Clinical trial · Observational
An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan
A Retrospective Observational Study to Investigate the Prevalence of NTRK Gene Fusion Positive in Solid Tumor in Japan
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational study in which data from the past of people with solid tumors harboring an NTRK gene fusion in Japan are studied. In observational studies, only observations are made without specified advice or interventions. Advanced or recurrent solid tumor harboring an NTRK gene fusion is a rare type of solid cancer caused by specific changes in the genes called NTRK gene fusion, and which has spread to nearby tissues and/or lymph nodes or has returned. Due to this change in the gene, an altered protein known as a TRK fusion protein is made, which can cause cancer cells to grow and survive. The main purpose of this study is to learn more about NTRK gene fusion in people in Japan. To do this, researchers will collect information on the number or percentage of Japanese people with NTRK gene fusion in any solid tumor. The data will come from the national database called C-CAT. They will cover the period from June 2019 until January 2023. Besides this data collection, no further tests or examinations are planned, and no visits are required in this study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No Drug | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with solid tumor and genome profiling results
- description
- Retrospective data analysis, the dataset for this study will be extracted from the C-CAT database.
- interventionNames
- Other: No Drug
Primary outcomes (2)
- measure
- Prevalence of patients with NTRK gene fusions by patient characteristic categories, such as tumor types
- timeFrame
- Retrospective data analysis from June 2019 to the latest data available (planned end of February 2023)
- measure
- Distribution of cancer types in patients with NTRK fusion positive among all, adult and pediatric
- timeFrame
- Retrospective data analysis from June 2019 to the latest data available (planned end of February 2023)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with any solid tumor and genome profiling results Exclusion Criteria: * None
References
Publications (1)
- DERIVEDNakata E, Osone T, Ogawa T, Taguchi T, Hattori K, Kohsaka S. Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan. Cancer Med. 2024 Jun;13(12):e7351. doi: 10.1002/cam4.7351. PMID 38925616